Editorial commentary: A rare event: A measles outbreak in a population with high 2-dose measles vaccine coverage

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 403-405

  Seward, Jane F ^a   Orenstein, Walter A ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY; MEASLES VACCINE;

AGE; ANTIBODY RESPONSE; CHILDHOOD; DEVELOPING COUNTRY; DISEASE SEVERITY; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPIDEMIC; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MEASLES; MEASLES VACCINATION; NOTE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; MEASLES; MEASLES VACCINE; VACCINATION;

EID: 84863887747     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis445     Document Type: Note

References (24)

1. Centers for Disease Control and Prevention. Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep 2009; 58:1321-6.
2. Strebel PM, Cochi SL, Hoekstra E, et al. A world without measles. J Infect Dis 2011; 204(Suppl 1):S1-3.
3. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, twodose vaccination program. N Engl J Med 1994; 331:1397-402.
4. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004; 189(Suppl 1):S1-3.
5. King A, Varughese P, De Serres G, Tipples GAWaters J, Working Group on Measles Elimination. Measles elimination in Canada. J Infect Dis 2004; 189(Suppl 1):S236-42.
6. Gidding HF, Wood J, MacIntyre CR, et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 2007; 25:3574-80.
7. Castillo-Solorzano CC, Matus CR, Flannery B, Marsigli C, Tambini G, Andrus JK. The Americas: paving the road toward global measles eradication. J Infect Dis 2011; 204(Suppl 1):S270-8.
8. Parker Fiebelkorn A, Redd SB, Gallagher K, et al. Measles in the United States during the postelimination era. J Infect Dis 2010; 202:1520-8.
9. Editorial team. Measles once again endemic in the United Kingdom. Euro Surveill 2008; 13:18919.
10. De Serres G, Boulianne N, Defay F, et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis 2012 [in this issue].
11. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 2011; 204(Suppl 1):S133-48.
12. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84:349-60.
13. Hersh BS, Markowitz LE, Hoffman RE, et al. A measles outbreak at a college with a prematriculation immunization requirement. Am J Public Health 1991; 81:360-4.
14. Mast EE, Berg JL, Hanrahan LP, Wassell JT, Davis JP. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. JAMA 1990; 264:2529-33.
15. Sutcliffe PA, Rea E. Outbreak of measles in a highly vaccinated secondary school population. CMAJ 1996; 155:1407-13.
16. Peltola H, Karanko V, Kurki T, et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1986; 1:137-9.
17. Centers for Disease Control and Prevention. Measles prevention. MMWR Morb Mortal Wkly Rep 1989; 38(Suppl 9):1-18.
18. Poland GA, Jacobson RM, Thampy AM, et al. Measles reimmunization in children seronegative after initial immunization. JAMA 1997; 277:1156-8.
19. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010; 340:c1626.
20. Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 2005; 116:1287-91.
21. Barrabeig I, Rovira A, Munoz P, et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine 2011; 29:8024-31.
22. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009; 360:1981-8.
23. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950-6.
24. LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294-301.